---
created: 2025-04-13
updated: 2025-04-13T10:52
id: M)NkUudL#L
specialty: cardio
specialty_id: 138
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::07-cardiovascular::05-pharm::11-cardiac-glycosides
  - "source/ak-step1-v11:": 
  - theme/firstaid::07-cardiovascular::05-pharm::11-cardiac-glycosides::digoxin
  - "source/ak-step1-v11:": 
  - theme/nbme::29
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::09-cardiac
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::10-cardiac::16-digoxin
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::02-cardio-&-renal::01-heart-failure-drugs::01-digoxin,-milrinone,-nesiritide
  - "source/ak-step1-v11:": 
  - theme/uworld::1000-9999::1000-1999::1882
  - source/ak-step1-v11::^other::^highyield::1-highyield
  - source/ak-step1-v11::^systems::cardio::pharmacology
type: flashcard
---

# Question
Cardiac glycosides (e.g. digoxin) lead to **increased** levels of intracellular Ca2+

---

# Answer
as a result of indirect inhibition of the Na+/Ca2+ exchanger   Ca2+ influx into the cytoplasm from the sarcoplasmic reticulum == myocyte contraction Removal of Ca2+ from the cytoplam when contraction is no longer needed (eg, during myocardial diastole) is critical